Z Squared (ZSQR) Registration filing summary

Company overview and business model

• Operates as a biopharmaceutical company focused on cell therapy technologies for cancer and other diseases, with a strategy centered on developing its product portfolio and forming strategic partnerships in oncology and autoimmune disease.

• Acquired key assets through mergers and licensing, including exclusive rights to stem cell expansion platforms and CAR-T technologies, and maintains collaborations with academic and industry partners.

• Product pipeline includes CD38-GEAR-NK (gene-edited NK cell therapy), CD38-Diagnostic (in vitro diagnostic tool), SNAP-CAR platform (universal CAR cell therapy), and unmodified NK cells for hematologic and respiratory diseases.

• Recent expansion includes acquisition of an AI-powered marketing and RPA platform to diversify revenue streams.

Financial performance and metrics

• Reported net losses of $21.3M for 2023 and $7.9M for the nine months ended September 30, 2024, with accumulated deficit rising to $95.2M.

• Minimal revenue generated to date, with no significant product revenue expected for at least two more years.

• Cash position was $1.1M as of September 30, 2024, down from $1.5M at year-end 2023; ongoing negative cash flow from operations.

• Operating expenses decreased year-over-year, primarily due to lower professional services and financing costs.

Use of proceeds and capital allocation

• May receive up to $20M in gross proceeds from sales of common stock to Yorkville under the Standby Equity Purchase Agreement (SEPA); proceeds intended for working capital and general corporate purposes.

• Raised $6.87M in Series A Preferred Stock in 2024, with proceeds supporting R&D in newly formed subsidiaries focused on GEAR and SNAP platforms.

• No proceeds from the resale of shares by selling stockholders; company retains broad discretion over use of SEPA proceeds.